Sector Expert: Anthony Vendetti

Maxim Group

Image: Anthony Vendetti

Anthony Vendetti is the director of research and senior healthcare analyst at Maxim Group, LLC. Mr. Vendetti has been on Wall Street for more than 20 years and follows the medical device, healthcare information technology and services industries. Prior to joining Maxim Group, he was a senior healthcare analyst at Gruntal, UBS Securities and Ladenburg Thalmann. Mr. Vendetti also worked for three years in the healthcare industry at CIGNA, ultimately as a senior healthcare analyst in the managed care division.



Recent Interviews

Viveve's Treatment for Improving Women's Sexual Function May Leapfrog the Competition (10/5/16)
Viveve Medical 3-month chart

Private-pay aesthetic procedures constitute a trend in medical devices, according to Anthony Vendetti, Director of Research at Maxim Group. These nonreimbursable types of procedures have seen rapid growth in the past decade. In this interview with The Life Sciences Report, Vendetti discusses Viveve Medical, which is attempting to leapfrog the competition to get FDA approval to use its patented radiofrequency technology to improve women's sexual function.

Recent Quotes

"VIVE reported Q1/18 revenue of $3.7M, up 21.6% year over year."

— Anthony Vendetti, Maxim Group (5/11/18)
more >

"VIVE's Q4/17 revenue of $5.1M was up 108% year over year."

— Anthony Vendetti, Maxim Group (3/16/18)
more >

"The net capital raised is sufficient to fund VIVE through 2019E."

— Anthony Vendetti, Maxim Group (2/12/18)
more >

"VIVE's preliminary Q4/17 revenue of ~$5.1M was up 108% YOY."

— Anthony Vendetti, Maxim Group (1/4/18)
more >

"We would continue to be buyers of VIVE after an in-line Q3/17."

— Anthony Vendetti, Maxim Group (11/9/17)
more >

"VIVE's Q3/17 revenue of approximately $4.1M was up roughly 122% YOY."

— Anthony Vendetti, Maxim Group (10/18/17)
more >

"We believe VIVE's Phase 3 trial is on track for a readout of data in mid-2019."

— Anthony Vendetti, Maxim Group (8/11/17)
more >

"We continue to be buyers of VIVE following its seventh consecutive quarter of double-digit revenue growth driven by a successful launch of the U.S. commercialization coupled with reaffirmed guidance."

— Anthony Vendetti, Maxim Group (5/12/17)
more >

more comments

"We believe VIVE's focus on attaining additional regulatory clearances, supporting its global distribution partners, expanding its direct sales force, and investing in market awareness, should position it for continued growth."

— Anthony Vendetti, Maxim Group (2/17/17)
more >

"We view VIVE's recent regulatory clearances as significant milestones (S. Korea, Brazil and the U.S.), as approval in these countries represents large market opportunities."

— Anthony Vendetti, Maxim Group (11/11/16)
more >

"Viveve has the technology, it's putting together a worldwide distribution network, and it has the management team to execute."

The Life Sciences Report Interview with Anthony Vendetti (10/5/16)
more >

"We would continue to be buyers of VIVE following its fourth consecutive quarter of double-digit revenue growth."

— Anthony Vendetti, Maxim Group (8/12/16)
more >

"VIVE is well-positioned to gain regulatory clearances in additional countries, which should lead to the Viveve System gaining further traction."

— Anthony Vendetti, Maxim Group (6/21/16)
more >

fewer comments


Due to permission requirements, not all quotes are shown.